Aclarion, Inc. (ACON)

NASDAQ: ACON · IEX Real-Time Price · USD
0.900
-0.020 (-2.22%)
Jul 5, 2022 10:49 AM EDT - Market open

Company Description

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and a proprietary biomarker to optimize clinical treatments.

The first application of Aclarion’s technology addresses the $134.5B U.S. low back and neck pain market. The Company, which has limited sales to date, is addressing this market by initially focusing on improving the outcomes of surgical interventions to treat low back pain.

In this initial application, Aclarion technology is intended to assist surgeons in determining the optimal surgical procedure for a patient undergoing surgery for pain isolated to their lumbar spine.

We then intend add additional applications of our technology targeting the management of large segments of low back pain patients from the point of initial MRI through to episode resolution.

The use of AI in this application is early in its development cycle and is expected to evolve with further research and development. The use of AI in this application is aspirational and we intend this type of AI research and development to be an ongoing process applied not only to the various treatment paths associated with back pain, but also to potentially expand into other clinical explorations involving the diagnosis of brain, breast and prostate tumors.

Aclarion, Inc.
Country United States
Founded 2008
IPO Date Apr 22, 2022
Industry Health Information Services
Sector Health Care
Employees 6
CEO Brent Ness

Contact Details

Address:
951 Mariners Island Blvd, Suite 300
San Mateo, CA 94404
United States
Phone 650-241-1741
Website nocimed.com

Stock Details

Ticker Symbol ACON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $4.35
CIK Code 1635077
ISIN Number US6551871022
SIC Code 8071

Key Executives

Name Position
Dr. Jeffrey John Thramann M.D. Executive Chairman
Brent Ness Chief Executive Officer, President and Director
John Lorbiecki Chief Financial Officer
Ryan Bond Chief Strategy Officer

Latest SEC Filings

Date Type Title
Jun 6, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 26, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 23, 2022 3/A Initial statement of beneficial ownership of securities
May 19, 2022 3/A Initial statement of beneficial ownership of securities
Apr 27, 2022 8-K Current report
Apr 25, 2022 4 Statement of changes in beneficial ownership of securities
Apr 25, 2022 4 Statement of changes in beneficial ownership of securities
Apr 25, 2022 3/A Initial statement of beneficial ownership of securities
Apr 25, 2022 4 Statement of changes in beneficial ownership of securities
Apr 25, 2022 4 Statement of changes in beneficial ownership of securities